Herein, we show that aberrant PIK3CD-S splice variant is overexpressed in aggressive African American prostate cancer, and its resulting PI3Kδ-S isoform is resistant to PI3Kδ inhibitors, such as Idelalisib and Seletalisib. Here, PIK3CD is linked to prostate carcinoma.